Skip to content

Search

The Importance of Scabies Co-Infection in the Treatment Considerations for Impetigo

Treatment success for scabies co-infection was lower than for impetigo overall, with a higher success seen in the co-trimoxazole group than benzylpenicillin

The inequitable burden of group A streptococcal diseases in Indigenous Australians

Given the ongoing mortality and morbidity from GAS infections, we must address more effectively the treatment and prevention of GAS impetigo and pharyngitis

Whole genome sequencing reveals extensive community-level transmission of group A Streptococcus in remote communities

There was evidence of extensive transmission of group A Streptococcus both within households and across the community

Nitazoxanide for the treatment of infectious diarrhoea in the Northern Territory, Australia 2007-2012

This paper examines the use of a new antibiotic to treat diarrhoea cause by Cryptosporidium infection in Australian Indigenous children.

Standardising and assessing digital images for use in clinical trials: A practical, reproducible method that blinds the assessor to treatment allocation

We describe the development and evaluation of a protocol for digital image collection by the non-professional photographer in a remote setting research trial

Scabies and impetigo in Timor-Leste: A school screening study in two districts

Scabies and impetigo are common in Timor-Leste, with very high prevalence of scabies in the rural district of Ermera

A Retrospective case-series of children with bone and joint infection from northern Australia

We report osteomyelitis incidence in indigenous children of northern Australia is amongst the highest reported in the world

A Systematic Framework for Prioritizing Burden of Disease Data Required for Vaccine Development and Implementation: The Case for Group A Streptococcal Diseases

Vaccine development and implementation decisions need to be guided by accurate and robust burden of disease data. We developed an innovative systematic framework outlining the properties of such data that are needed to advance vaccine development and evaluation, and prioritize research and surveillance activities.